Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
443 studies found for:    Open Studies | "Hormones"
Show Display Options
Rank Status Study
21 Recruiting EXTEND Exercise Trial
Condition: Non-metastatic, Hormone naïve Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: Androgen deprivation therapy;   Behavioral: Supervised exercise training
22 Recruiting A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Conditions: Growth Hormone Deficiency, Pediatric;   hGH (Human Growth Hormone);   Endocrine System Diseases;   Hormones;   Pituitary Diseases
Interventions: Drug: Once weekly subcutaneous injection of TransCon hGH;   Drug: Once daily subcutaneous injection of Genotropin
23 Not yet recruiting Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cabazitaxel;   Drug: Prednisone
24 Recruiting Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
25 Recruiting Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer
Intervention: Drug: Everolimus plus Exemestane
26 Recruiting A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer;   Hormone Receptor Positive
Intervention: Drug: Palbociclib
27 Not yet recruiting Dynamic Hormone Diagnostics in Endocrine Disease
Conditions: Adrenal Insufficiency;   Congenital Adrenal Hyperplasia;   Cushing Syndrome;   Growth Hormone Deficiency;   Acromegaly;   Primary Hyperaldosteronism
Intervention: Other: 27 hour subcutaneous fluid sampling
28 Recruiting A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders
Condition: Growth Hormone Disorders
Intervention:
29 Recruiting Hormone Replacement for Premature Ovarian Insufficiency
Condition: Primary Ovarian Insufficiency
Interventions: Drug: Hormone Replacement Therapy;   Drug: Combined Oral Contraceptives
30 Recruiting Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA and ISS in Children
Conditions: Growth Hormone Deficiency;   Turner Syndrome;   Chronic Renal Failure;   Small for Gestational Age;   Idiopathic Short Stature
Intervention:
31 Not yet recruiting ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: ODM-201;   Drug: ADT
32 Recruiting Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
Condition: Multiple Sclerosis
Interventions: Drug: Liothyronine sodium;   Drug: Placebo
33 Recruiting Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Estrogen Receptor Positive Breast Cancer;   Progesterone Receptor Positive Tumor;   Metastatic Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Tamoxifen
34 Not yet recruiting The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment
Condition: Hormone Refractory Prostate Cancer
Intervention: Drug: Carboplatin
35 Not yet recruiting PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Condition: Hormone Refractory Prostate Cancer
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
36 Recruiting Radiotherapy vs Observation for CRPC
Condition: Hormone Refractory Prostate Cancer
Intervention:
37 Recruiting The Gender-Sex Hormone Interface With Craving & Stress-Related Changes in Smoking
Condition: Nicotine Dependence
Interventions: Drug: Oxytocin;   Drug: placebo
38 Recruiting Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification
Condition: Breast Neoplasms
Interventions: Drug: Tamoxifen;   Drug: Vorinostat;   Drug: pembrolizumab
39 Recruiting Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer
Condition: Prostate Cancer
Intervention: Other: Blood drawing
40 Not yet recruiting Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: Radiotherapy to the pelvis;   Drug: Hormonal therapy (LHRH agonist and/or antiandrogens)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.